Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 1 of 7212345...102030...Last »

Biogen Spinoff Bioverativ Buying True North

Bioverativ is buying True North Therapeutics for an upfront payment of $400 million and up to $425 million in milestones.

Read More »

Biogen Acquires Remedy Pharmaceuticals’ Cirara

Remedy Pharmaceuticals announced that Biogen completed an asset purchase of its Phase 3 candidate, Cirara.

Read More »

X-Chem, Vertex Enter into Collaboration

X-Chem announced a collaboration with Vertex for the discovery of small-molecule leads against validated targets for severe, genetic diseases.

Read More »

Thermo Fisher Scientific acquires Patheon

Thermo Fisher Scientific Inc. snapped up North Carolina-based Patheon N.V. in a deal valued at $7.2 billion.

Read More »

Pfizer strikes deal with Sangamo, broadening hemophilia pipeline

U.S. drugmaker Pfizer Inc. reached an agreement with Sangamo Therapeutics Inc. for rights to its gene therapy programs to treat the rare blood-clotting disorder hemophilia A.

Read More »

Sanofi pegs U.S. drug price rises to below healthcare inflation

Sanofi pledged to peg U.S. drug price rises to below healthcare inflation, limits 2017 increases to 5.4 percent.

Read More »

Amgen Eying Two Biotechs’ Shark Antibodies

Amgen may need a bigger boat. The company is eying the use of shark-inspired antibodies called soloMERs to go after two undisclosed intracellular targets.

Read More »

J&J discloses U.S. probe related to arthritis drugs

Healthcare conglomerate Johnson & Johnson said the U.S. Justice Department opened an investigation concerning management and advisory services provided to rheumatology and gastroenterology practices that bought two of its drugs.

Read More »

Durect Snags Pain Drug Pact With Novartis

Durect Corporation inked a development and commercialization deal with Sandoz AG, a division of Novartis AG, totaling around $293 million.

Read More »

Array BioPharma, Merck Strategic Collaboration

Array BioPharma entered into a clinical trial collaboration with Merck to study a novel drug combo for colorectal cancer patients with microsatellite stable tumors.

Read More »

Immunomedics CEO, COO Exit

Immunomedics’ chief executive office and chief scientific officer will step down. Also, Seattle Genetics backed out of a $2 billion deal with the company.

Read More »

J&J ordered to pay $110 million in U.S. talc-powder trial

Johnson & Johnson was ordered by a Missouri jury to pay over $110 million to a Virginia woman who says she developed ovarian cancer after decades of using of its talc-based products for feminine hygiene.

Read More »

U.S. sues UnitedHealth for false claims

The Justice Department accused UnitedHealth of obtaining inflated risk adjustment payments based on inaccurate info about patients’ health status.

Read More »

Pfizer Axes 3 Drugs From Pipeline in Q1 2017

In Pfizer’s first-quarter 2017 financial report, total revenue was down 2 percent year over year. The company also reported three discontinued pipeline projects.

Read More »

AbbVie profit beats on Humira demand

AbbVie Inc. reported a larger-than-expected first-quarter 2017 profit, lifted by demand for the company’s flagship drug Humira.

Read More »

AstraZeneca Dumps Two Drugs From Pipeline

As AstraZeneca faces declining revenue in 2017 from the loss of patents and the challenge of generic drugs, the company culled two drugs from its pipeline.

Read More »

South Korea fines Novartis $49 million over kickbacks

South Korea fined Swiss drugmaker Novartis 55.1 billion won ($48.80 million) for offering doctors kickbacks to recommend the company’s drugs.

Read More »

Finance chief quits drugmaker Teva

Teva Pharmaceutical Industries’ finance chief Eyal Desheh will step down, the second top official to resign from the Israel-based company during 2017.

Read More »

Covance Cuts 100+ Employees in Shut Down

Princeton, N.J.-based CRO Covance plans to shutter its lab in Evansville, Ind., in summer 2017. More than 100 staffers are expected to be laid off.

Read More »

Novartis sets sights on return to growth in 2018

Novartis reported better-than-expected first-quarter 2017 profits with CEO Joe Jimenez remaining confident the Swiss drugmaker would return to growth in 2018.

Read More »

Page 1 of 7212345...102030...Last »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

April 2017 Focus: Agency Profiles, Manny Awards and more!


Ad Right Bottom

Password Reset
Please enter your e-mail address. You will receive a new password via e-mail.

Main Navigation